Oritavancin
Single-dose lipoglycopeptide for skin infections.
What it is
Oritavancin (Orbactiv, Kimyrsa) is a single-dose lipoglycopeptide antibiotic FDA-approved for acute bacterial skin and skin structure infections caused by susceptible gram-positive organisms. The very long half-life allows complete treatment with a single dose.
Mechanism of action
Inhibits bacterial cell wall synthesis. Active against gram-positive organisms including MRSA. The very long half-life (~245 hours) supports single-dose treatment regimens.
Approved indications
Acute bacterial skin and skin structure infections.
Why this is out of scope at The Tide
IV antibiotic for serious infections, administered in hospital or infusion-center settings under appropriate physician care. Not appropriate for outpatient peptide clinic.
Where to learn more
Infectious disease, emergency medicine, or hospital-based providers.